154TiP AdvanTIG-204: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus anti-PD-1 mAb tislelizumab (TIS) plus concurrent chemoradiotherapy (cCRT) in patients (pts) with untreated limited-stage small cell lung cancer (LS-SCLC)
Year: 2022
Type: article
Source: Annals of Oncology
Authors: Y. Lu, Y. Gong, J-H. Kang, J. Whan Ree, X. Chen, X. Lin, J. Zhang, H. Borghaei
Institutions: Sichuan University, West China Medical Center of Sichuan University, West China Hospital of Sichuan University, State Key Laboratory of Biotherapy, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, BeiGene (China), Fox Chase Cancer Center, Temple University
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4225960939